Overview
- Species: Porcine
- Keywords: HyStem®/hyaluronic acid
- Specific Attributes: sterile
Gelin-S® Thiol-modified Gelatin
Cat.-Nr.: GS231-5EA
Description
Gelin-S® is thiol-modified gelatin (denatured collagen) and is a component of the HyStem®-C, and HyStem-HP hydrogel kits. Most cells do not grow well on Gelin-S–only hydrogels. Instead, Gelin-S should be used in conjunction with Glycosil® (thiol-modified hyaluronic acid) or Heprasil® (thiol-modified hyaluronic acid with thiol-modified heparin). Reconstituted Gelin-S remains liquid at 15 to 37°C.
The gelatin used to make Gelin-S is from Type A Gelatin, Bloom 250, derived from porcine skin.
Gelin-S® (thiol-modified gelatin) is packaged in 5 x 1.0 mL vials containing 10mg. Vials are blanketed by nitrogen and under a slight vacuum.
Store Gelin-S in the original vial, unopened, at -20 °C for up to one year. Do not uncap the Gelin-S vials since they will crosslink in the presence of oxygen. Use a syringe and needle to add DG Water to the vials.
Note: It is recommended to reconstitute each vial in its entirety.
SUPPLIER:
Advanced BioMatrix
STATUS:
In Stock
SIZE:
5 x 1 ml
Related Files
References
- References for HyStem®:
- Maloney, E. et al.Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines 11, 208 (2020).
- Gaetani, R., et al. (2015) Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 61: 339-348. PMID: 17335875.
- Prestwich, G.D., et al. (2007) 3-D culture in synthetic extracellular matrices: new tissue models for drug toxicology and cancer drug discovery. Adv Enzyme Regul 47: 196-207. PMID: 17335875.
- Shu, X.Z., et al. (2006) Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A 79: 901-912. PMID: 16941590.
- Shu, X.Z., et al. (2003) Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 24: 3825-3834. PMID: 12818555.
- Cai, et al. (2005) Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.Biomaterials, 26, 6054-6067.
- B. Pike, et al. (2006) Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials, 27, 5242–5251.
- D. Prestwich, et al. (2007) 3-D Culture in Synthetic Extracellular Matrices: New Tissue Models for Drug Toxicology and Cancer Drug Discovery. invited, Adv. Enz. Res., in press (2007).
- Z. Shu, et al, (2006) Synthesis and Evaluation of Injectable, In Situ Crosslinkable Synthetic Extracellular Matrices (sECMs) for Tissue Engineering. J. Biomed Mater. Res. A, 79A(4), 901-912.
- Shu, X.Z., et al. (2004) In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25: 1339-1348. PMID: 14643608.
- Mehra, T.D., et al. (2006) Molecular stenting with a crosslinked hyaluronan derivative inhibits collagen gel contraction. J Invest Dermatol 126: 2202-2209. PMID: 16741511.
- Shu, X.Z., et al. (2004) Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 68: 365-375. PMID: 14704979.
- Ghosh, K., et al. (2007) Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 28: 671-679. PMID: 17049594.
Extralink® PEGDA